Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Immunome stock

IMNM
US45257U1088
A2QD9D

Price

9.91
Today +/-
-1.17
Today %
-11.74 %
P

Immunome stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Immunome stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Immunome stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Immunome stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Immunome's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Immunome Stock Price History

DateImmunome Price
11/15/20249.91 undefined
11/14/202411.14 undefined
11/13/202412.38 undefined
11/12/202412.49 undefined
11/11/202413.26 undefined
11/8/202412.98 undefined
11/7/202412.54 undefined
11/6/202413.10 undefined
11/5/202412.97 undefined
11/4/202412.81 undefined
11/1/202411.59 undefined
10/31/202411.47 undefined
10/30/202412.20 undefined
10/29/202412.20 undefined
10/28/202412.43 undefined
10/25/202412.11 undefined
10/24/202412.01 undefined
10/23/202411.60 undefined
10/22/202411.71 undefined
10/21/202411.91 undefined
10/18/202412.28 undefined

Immunome Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immunome, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immunome from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immunome’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immunome. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immunome’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immunome’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immunome’s growth potential.

Immunome Revenue, EBIT and net profit per share

DateImmunome RevenueImmunome EBITImmunome Net Income
2029e251.59 M undefined0 undefined133.43 M undefined
2028e170.84 M undefined-93.33 M undefined-6.99 M undefined
2027e69.85 M undefined-183.18 M undefined-138.19 M undefined
2026e19.72 M undefined-226.29 M undefined-197.17 M undefined
2025e0 undefined-196.76 M undefined-184.22 M undefined
2024e8.57 M undefined-252.45 M undefined-259.23 M undefined
202314.02 M undefined-28.73 M undefined-106.81 M undefined
20220 undefined-36.9 M undefined-37.52 M undefined
20210 undefined-25.2 M undefined-24.71 M undefined
20200 undefined-12.26 M undefined-17.84 M undefined
20190 undefined-10.35 M undefined-10.44 M undefined
20180 undefined-7.74 M undefined-7.85 M undefined

Immunome Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
0000014801969170251
-------42.86--263.16146.3847.65
------------
000000000000
-7-10-17-24-37-106-259-184-197-138-6133
-42.8670.0041.1854.17186.49144.34-28.967.07-29.95-95.65-2,316.67
9.289.2810.6611.5412.1319.84000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Immunome Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Immunome is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
1.62.5439.7749.2320.32138.14
000000
000000
000000
0.510.583.137.411.486.56
2.113.1242.956.6421.8144.7
2.081.71.530.860.973.64
000000
000000
000000
000000
260240100430430200
2.341.941.631.291.43.84
4.455.0644.5357.9323.2148.54
           
27.5138.890000
0.910.9395.74127.29132.65342.66
-26.11-36.56-54.39-79.11-116-222.81
0000022
000000
2.313.2641.3548.1816.65119.88
0.470.551.193.082.43.31
0.480.671.376.654.937.83
0000010.69
000000
610450480000
1.561.673.049.737.3321.83
560110130000
000000
0.020.020.010.010.066.83
0.580.130.140.010.066.83
2.141.83.189.747.3928.66
4.455.0644.5357.9224.04148.54
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Immunome provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Immunome's financial health and stability.

Assets

Immunome's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Immunome must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Immunome after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Immunome's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
-7-10-17-24-36
00000
00000
00-122
006610
00000
00000
-7-9-12-18-28
00000
00000
00000
00000
06000
0455280
01049270
---5.00--
00000
-80379-28
-7.64-9.83-12.72-18.31-28.94
00000

Immunome stock margins

The Immunome margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunome. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunome.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immunome's sales revenue. A higher gross margin percentage indicates that the Immunome retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immunome's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immunome's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immunome's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immunome. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immunome's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immunome Margin History

Immunome Gross marginImmunome Profit marginImmunome EBIT marginImmunome Profit margin
2029e0 %0 %53.03 %
2028e0 %-54.63 %-4.09 %
2027e0 %-262.24 %-197.84 %
2026e0 %-1,147.7 %-1,000.01 %
2025e0 %0 %0 %
2024e0 %-2,946.81 %-3,025.87 %
20230 %-204.94 %-761.92 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %

Immunome Stock Sales Revenue, EBIT, Earnings per Share

The Immunome earnings per share therefore indicates how much revenue Immunome has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immunome earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immunome's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immunome’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immunome's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immunome Revenue, EBIT and net profit per share

DateImmunome Sales per ShareImmunome EBIT per shareImmunome Earnings per Share
2029e4.04 undefined0 undefined2.14 undefined
2028e2.74 undefined0 undefined-0.11 undefined
2027e1.12 undefined0 undefined-2.22 undefined
2026e0.32 undefined0 undefined-3.17 undefined
2025e0 undefined0 undefined-2.96 undefined
2024e0.14 undefined0 undefined-4.16 undefined
20230.71 undefined-1.45 undefined-5.38 undefined
20220 undefined-3.04 undefined-3.09 undefined
20210 undefined-2.18 undefined-2.14 undefined
20200 undefined-1.15 undefined-1.67 undefined
20190 undefined-1.12 undefined-1.13 undefined
20180 undefined-0.83 undefined-0.85 undefined

Immunome business model

Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome is one of the most popular companies on Eulerpool.com.

Immunome SWOT Analysis

Strengths

Immunome Inc has a strong research and development team consisting of experienced scientists and experts in immunology, providing them with the ability to effectively develop novel immunotherapies and vaccines.

The company's extensive intellectual property portfolio gives them a competitive advantage by protecting their innovative products from competitors.

Immunome Inc has established strategic partnerships with leading pharmaceutical companies, enabling them to access additional resources, funding, and distribution channels.

Weaknesses

The company heavily relies on external funding sources, such as grants and partnerships, which exposes them to uncertainties and potential funding gaps.

Immunome Inc may face challenges in effectively marketing and commercializing their products, as the immunotherapy market is highly competitive and dominated by well-established players.

The company's success is significantly dependent on the results of their ongoing clinical trials, and any setbacks or failures could have a negative impact on their reputation and finances.

Opportunities

The increasing demand for personalized medicine and targeted therapies presents an opportunity for Immunome Inc to leverage their expertise in immunology and develop tailored treatments.

Advancements in technology and genomic research enable Immunome Inc to further enhance their understanding of immunology and develop more effective immunotherapies with improved safety profiles.

The expanding global healthcare market, particularly in regions like Asia-Pacific, provides Immunome Inc with the potential to expand their reach and tap into new markets.

Threats

Intense competition from both established pharmaceutical companies and emerging biotech firms poses a threat to Immunome Inc's market share and profitability.

Regulatory uncertainties and evolving healthcare policies can impact the company's ability to gain necessary approvals for their products and navigate reimbursement challenges.

Unforeseen scientific or technological breakthroughs by competitors could potentially render Immunome Inc's existing products less effective or obsolete.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Immunome Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Immunome historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Immunome shares outstanding

The number of shares was Immunome in 2023 — This indicates how many shares 19.844 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immunome earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immunome's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immunome’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immunome's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Immunome.

Immunome latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.4 -0.49  (-22.13 %)2024 Q2
3/31/2024-0.71 -2.51  (-254.67 %)2024 Q1
12/31/2023-0.29 -4.22  (-1,360.21 %)2023 Q4
6/30/2023-0.16 -0.46  (-181.86 %)2023 Q2
3/31/20230.6 -0.35  (-158.66 %)2023 Q1
12/31/2022-0.69 -0.64  (7.04 %)2022 Q4
9/30/2022-0.78 -0.75  (3.25 %)2022 Q3
6/30/2022-0.77 -0.74  (3.27 %)2022 Q2
3/31/2022-0.7 -0.96  (-36.4 %)2022 Q1
12/31/2021-0.83 -0.68  (17.7 %)2021 Q4
1
2

Eulerpool ESG Scorecard© for the Immunome stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

37

👫 Social

44

🏛️ Governance

25

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Immunome shareholders

%
Name
Stocks
Change
Date
7.84966 % Redmile Group, LLC4,889,55406/30/2024
6.76022 % Fidelity Management & Research Company LLC4,210,943-323,7006/30/2024
6.22799 % EcoR1 Capital, LLC3,879,41506/30/2024
6.22667 % T. Rowe Price Investment Management, Inc.3,878,5952,362,1416/30/2024
5.58398 % Immunome Aggregator LP3,478,2613,478,26110/2/2023
5.45519 % BlackRock Institutional Trust Company, N.A.3,398,0362,614,0206/30/2024
5.07868 % Janus Henderson Investors3,163,5071,625,0936/30/2024
4.67725 % The Vanguard Group, Inc.2,913,462901,4746/30/2024
4.15901 % Arsenal Bridge Advisors, LLC2,590,648176,2678/21/2024
3.79553 % State Street Global Advisors (US)2,364,2342,163,5436/30/2024
1
2
3
4
5
...
10

Most common questions regarding Immunome

What values and corporate philosophy does Immunome represent?

Immunome Inc represents a strong commitment to innovation, cutting-edge research, and the development of novel immunotherapies. The company's corporate philosophy revolves around harnessing the power of the immune system to target and treat diseases, with a particular focus on cancer and infectious diseases. With a team of highly skilled scientists and industry experts, Immunome Inc is dedicated to discovering and advancing breakthrough therapies that can make a meaningful impact in patients' lives. By combining deep knowledge of the immune system with advanced technologies, Immunome Inc strives to deliver transformative treatments to address unmet medical needs.

In which countries and regions is Immunome primarily present?

Immunome Inc is primarily present in the United States.

What significant milestones has the company Immunome achieved?

Immunome Inc. has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2020, raising $26 million. In January 2021, Immunome entered into a collaboration agreement with AbCellera to discover and develop antibodies for infectious diseases. This collaboration aims to leverage Immunome's proprietary discovery engine, IMM-BCP, to select and optimize therapeutic candidates. In addition, Immunome has received funding from various sources, including the National Institutes of Health (NIH), to support the development of its pipeline and advance its immunotherapy programs. These milestones demonstrate Immunome Inc.'s progress and commitment to advancing innovative solutions in the field of immunology.

What is the history and background of the company Immunome?

Immunome Inc is a biotechnology company focused on discovering and developing novel immunotherapies for treating cancers and infectious diseases. Founded in [year], Immunome has already achieved significant milestones in its journey. The company's team of scientists and researchers utilize cutting-edge technologies to identify and isolate highly effective antibodies that can specifically target disease-causing agents. Immunome's groundbreaking work has garnered recognition in the scientific community and has attracted collaborations with leading pharmaceutical companies. With a vision to revolutionize the field of immunotherapy, Immunome Inc continues to advance its pipeline of potential treatments, offering hope for patients worldwide.

Who are the main competitors of Immunome in the market?

The main competitors of Immunome Inc in the market are other companies operating in the biotechnology and pharmaceutical industries. These competitors may include companies such as Moderna Inc, BioNTech SE, Pfizer Inc, Johnson & Johnson, and Novavax Inc. Immunome Inc faces competition in the development and commercialization of novel immunotherapies and vaccines. It continuously strives to differentiate itself through its innovative pipeline, cutting-edge technology, and strong research capabilities.

In which industries is Immunome primarily active?

Immunome Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Immunome?

The business model of Immunome Inc is focused on developing targeted antibody therapies for the treatment of cancer and other diseases. The company utilizes its proprietary discovery engine, known as IMM-01, to identify novel disease-targeting antigens and generate highly specific monoclonal antibodies. These therapeutic antibodies have the potential to selectively bind to disease-related targets, thereby stimulating an immune response against cancer cells or other disease-causing agents. Through its research and development efforts, Immunome aims to advance its pipeline of antibody candidates and potentially revolutionize the treatment options available for patients.

What is the P/E ratio of Immunome 2024?

The Immunome P/E ratio is -0.76.

What is the P/S ratio of Immunome 2024?

The Immunome P/S ratio is 22.94.

What is the Quality Investing of Immunome?

The Quality Investing for Immunome is 2/10.

What is the revenue of Immunome 2024?

The expected Immunome revenue is 8.57 M USD.

How high is the profit of Immunome 2024?

The expected Immunome profit is -259.23 M USD.

What is the business model of Immunome

Immunome Inc is an innovative biotechnology company specializing in the development of biopharmaceuticals for the treatment of autoimmune diseases and cancer. The company uses its proprietary platform technologies to identify antibodies that specifically bind to target molecules. These antibodies can then be used as therapeutics or biomarkers for disease diagnosis. The company has two main business areas: 1. Research and development of biopharmaceuticals: The company uses its proprietary sequencing and data analytics platform to identify unique antibodies that selectively target disease targets. Immunome has already developed several antibody candidates that are being tested in clinical trials for the treatment of autoimmune diseases and cancer. 2. Diagnostics: Immunome also offers diagnostic solutions based on its proprietary technologies. The company provides molecular diagnostic tests for identifying pathogens in blood and other bodily fluids. These tests enable faster and more accurate diagnosis of infectious diseases and can help detect and combat outbreaks of infectious diseases early on. Immunome aims to offer its customers high-quality products and solutions based on the latest scientific knowledge and technologies. The company invests heavily in research and development to further improve its technologies and products and to find new applications. Some of Immunome's key products include: 1. IMM-01: A novel antibody candidate targeting a target molecule that is overexpressed in autoimmune diseases such as rheumatoid arthritis and lupus. IMM-01 is currently in clinical trials and shows promising results in improving symptoms of autoimmune diseases. 2. IMM-101: An antibody candidate targeting a target molecule expressed in certain types of cancer such as pancreatic cancer and breast cancer. IMM-101 is currently being tested in clinical trials and could be a promising new therapy for cancer patients. 3. Molecular diagnostic tests: Immunome offers a range of molecular diagnostic tests, including tests for identifying bacteria and viruses that cause infectious diseases such as Lyme borreliosis and respiratory infections. Overall, Immunome has a promising business model based on its proprietary technology platform and its focus on developing a new generation of biopharmaceuticals and diagnostic solutions. The company has already developed promising products and is on a strong growth trajectory. By continuously investing in research and development and expanding its product line, Immunome will continue to play a leading role in the biotechnology industry.

What is the Immunome dividend?

Immunome pays a dividend of 0 USD distributed over payouts per year.

How often does Immunome pay dividends?

The dividend cannot currently be calculated for Immunome or the company does not pay out a dividend.

What is the Immunome ISIN?

The ISIN of Immunome is US45257U1088.

What is the Immunome WKN?

The WKN of Immunome is A2QD9D.

What is the Immunome ticker?

The ticker of Immunome is IMNM.

How much dividend does Immunome pay?

Over the past 12 months, Immunome paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunome is expected to pay a dividend of 0 USD.

What is the dividend yield of Immunome?

The current dividend yield of Immunome is .

When does Immunome pay dividends?

Immunome pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunome?

Immunome paid dividends every year for the past 0 years.

What is the dividend of Immunome?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunome located?

Immunome is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunome kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunome from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Immunome pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Immunome in the year 2023?

In the year 2023, Immunome distributed 0 USD as dividends.

In which currency does Immunome pay out the dividend?

The dividends of Immunome are distributed in USD.

All fundamentals about Immunome

Our stock analysis for Immunome Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.